Abbott Laboratories vs. MacroGenics, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABT | MGNX | |
|---|---|---|
| Market Cap | $175.27 billion | $238.24 million |
| Revenue (TTM) | $46.59 billion | $153.62 million |
| Net Income (TTM) | $5.42 billion | $-14,592,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | MGNX | |
|---|---|---|
| P/E Ratio | 32.78 | — |
| Price / Book | 3.39 | 5.56 |
| Price / Sales | 3.76 | 1.55 |
ABT and MGNX split the valuation factors evenly.
Profitability
| ABT | MGNX | |
|---|---|---|
| Net Margin | 11.65% | -9.50% |
| Return on Equity | 10.48% | -34.04% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | MGNX | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 81.55 | — |
ABT and MGNX split the dividend factors evenly.
Risk & Sentiment
| ABT | MGNX | |
|---|---|---|
| Short Interest | 0.57% | 7.54% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, MGNX overview, MGNX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.